{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:23:00Z","timestamp":1780424580046,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A13485"],"award-info":[{"award-number":["A13485"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","award":["2011-002882-39"],"award-info":[{"award-number":["2011-002882-39"]}],"id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022011","name":"CRUK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ctro.2023.100614","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T11:25:13Z","timestamp":1678533913000},"page":"100614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study"],"prefix":"10.1016","volume":"40","author":[{"given":"Hamid","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0440-2205","authenticated-orcid":false,"given":"Andrew","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ctro.2023.100614_b0005","first-page":"1623","article-title":"CRT of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u201301)","volume":"281","author":"Cooper","year":"1999","journal-title":"Radiat. Ther. Oncol. Group Jama"},{"key":"10.1016\/j.ctro.2023.100614_b0010","doi-asserted-by":"crossref","unstructured":"Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and RT compared with RT alone in patients with cancer of the esophagus. N Engl J Med 1992;326(24):1593-8.","DOI":"10.1056\/NEJM199206113262403"},{"issue":"22","key":"10.1016\/j.ctro.2023.100614_b0015","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ctro.2023.100614_b0020","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100614_b0025","unstructured":"Lynparza (olaparib) [prescribing information]Wilmington, Delaware: AstraZeneca Pharmaceuticals LP; Aug, 2017."},{"key":"10.1016\/j.ctro.2023.100614_b0030","unstructured":"Olaparib: side-effects. In: Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain. Accessed 27th Feb 2023. Available from: https:\/\/bnf.nice.org.uk\/drugs\/olaparib\/#side-effects."},{"issue":"3","key":"10.1016\/j.ctro.2023.100614_b0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/pr.54.3.375","article-title":"The therapeutic potential of poly(ADP-ribose) polymerase inhibitors","volume":"54","author":"Virag","year":"2002","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.ctro.2023.100614_b0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pbiomolbio.2004.01.001","article-title":"Poly(ADP-Ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications","volume":"88","author":"Nguewa","year":"2005","journal-title":"Prog Biophys Mol Biol"},{"issue":"7","key":"10.1016\/j.ctro.2023.100614_b0045","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","article-title":"Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial","volume":"14","author":"Crosby","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2023.100614_b0050","doi-asserted-by":"crossref","unstructured":"Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, et al. Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer. Clin Cancer Res. 2018 Oct 15;24(20):4949-4959. doi: 10.1158\/1078-0432.CCR-18-0467. Epub 2018 Jul 3. PMID: 30084837; PMCID: PMC6873707.","DOI":"10.1158\/1078-0432.CCR-18-0467"},{"key":"10.1016\/j.ctro.2023.100614_b0055","doi-asserted-by":"crossref","unstructured":"de Haan R, van den Heuvel MM, van Diessen J, Peulen HMU, van Werkhoven E, de Langen AJ, et al. Phase I and Pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer. Clin Cancer Res. 2021 Mar 1;27(5):1256-1266. doi: 10.1158\/1078-0432.CCR-20-2551. Epub 2020 Dec 1. PMID: 33262140.","DOI":"10.1158\/1078-0432.CCR-20-2551"},{"issue":"10","key":"10.1016\/j.ctro.2023.100614_b0060","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/ijc.33737","article-title":"Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial","volume":"149","author":"Loap","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ctro.2023.100614_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5413-y","article-title":"Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol","volume":"19","author":"Lesueur","year":"2019","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.ctro.2023.100614_b0070","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.3390\/cancers13215380","article-title":"PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?","volume":"13","author":"Barcellini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2023.100614_b0075","doi-asserted-by":"crossref","unstructured":"Hodgson D, Mason H, Oplustilova L, et al. Activity of the PARP inhibitor olaparib in ATM deficient gastric cancer: From preclinical models to the clinic. Proc Am Assoc Cancer Res 2014;74: abstr 2398.","DOI":"10.1158\/1538-7445.AM2014-2398"},{"issue":"13","key":"10.1016\/j.ctro.2023.100614_b0080","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.4161\/cc.29212","article-title":"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines","volume":"13","author":"Kubota","year":"2014","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.ctro.2023.100614_b0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000346034","article-title":"Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients","volume":"80","author":"Kim","year":"2013","journal-title":"Pathobiology"},{"issue":"33","key":"10.1016\/j.ctro.2023.100614_b0090","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, DoubleBlind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100614_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/annonc\/mdw435.16","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study","volume":"27","author":"Bang","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2023.100614_b0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clon.2019.09.058","article-title":"Outcome of weekly carboplatin-paclitaxel-based definitive chemoradiation in oesophageal cancer in patients not considered to be suitable for platinum-fluoropyrimidine-based treatment: A multicentre, retrospective review","volume":"32","author":"Owens","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:11:16Z","timestamp":1762503076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630823000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":20,"alternative-id":["S2405630823000393"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100614","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100614"}}